They finally going the route they should have so many years ago. GW Pharma (GWPH) developed an experimnental drug derived from marijuana and just passed another critical hurdle toward being approved to treat certain kinds of epilepsy.
Lennox-Gastaut Syndrome is a rare form of childhood-onset epilepsy that’s associated ith multiple types of seizures.
A Phase 3 trial reported Monday, found that the drug, Epidiolex, was more effective reducing the number of seizures in patients then placebo medication by 22%.
Steve Schultz, GW’s vice president of investor relations, said the difference would be in the uniformity of the product.
“The products that people are using, and purchasing, they’re artisanal products.”
That means they can vary by batch and can be influenced by different fertilizers or pesticides. GW’s version wouldn’t.
“It will have the hallmarks of a true pharmaceutical medicine.”
Read more here>>>